• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国接受中医药治疗的肺癌患者的健康相关生活质量和效用评分

Health-Related Quality of Life and Utility Scores of Lung Cancer Patients Treated with Traditional Chinese Medicine in China.

作者信息

Liu Liu, Wei Yan, Teng Yue, Yan Juntao, Li Fuming, Chen Yingyao

机构信息

School of Public Health, Fudan University, Shanghai, People's Republic of China.

NHC Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, People's Republic of China.

出版信息

Patient Prefer Adherence. 2022 Feb 4;16:297-306. doi: 10.2147/PPA.S344622. eCollection 2022.

DOI:10.2147/PPA.S344622
PMID:35153476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8824292/
Abstract

PURPOSE

To assess health-related quality of life (HRQoL) and utility scores of lung cancer patients treated with traditional Chinese medicine (TCM) in China.

METHODS

This cross-sectional study included lung cancer patients treated with TCM in seven tertiary hospitals in Shanghai, China. The HRQoL and utility scores of these patients were measured using the five-level EQ-5D (EQ-5D-5L). The EQ-5D-5L utility scores were derived from the Chinese EQ-5D-5L Value Set. The relationships between HRQoL and the socio-demographic and clinical characteristics of these patients were further explored by Tobit regression.

RESULTS

This study included a total of 347 patients. Their mean ± SD and median EQ-5D-5L utility scores were 0.851 ± 0.198 and 0.893, respectively. The highest proportion of participants reporting problems was observed in pain/discomfort dimension (57.9%) and anxiety/depression (45.5%). Lung cancer patients treated with TCM had poor HRQoL, influenced by cancer clinical stage.

CONCLUSION

Lung cancer patients treated with TCM have poor HRQoL, with many patients reporting problems in the pain/discomfort and anxiety/depression dimensions. The information on health utility scores and HRQoL of lung cancer patients treated with TCM could be useful for future supportive care, economic evaluations and decision-making in China.

摘要

目的

评估在中国接受中医治疗的肺癌患者的健康相关生活质量(HRQoL)和效用得分。

方法

这项横断面研究纳入了在中国上海七家三级医院接受中医治疗的肺癌患者。使用五级EQ-5D(EQ-5D-5L)对这些患者的HRQoL和效用得分进行测量。EQ-5D-5L效用得分源自中国EQ-5D-5L价值集。通过Tobit回归进一步探讨HRQoL与这些患者的社会人口统计学和临床特征之间的关系。

结果

本研究共纳入347例患者。他们的平均±标准差和中位数EQ-5D-5L效用得分分别为0.851±0.198和0.893。在疼痛/不适维度(57.9%)和焦虑/抑郁(45.5%)中观察到报告问题的参与者比例最高。接受中医治疗的肺癌患者HRQoL较差,受癌症临床分期影响。

结论

接受中医治疗的肺癌患者HRQoL较差,许多患者在疼痛/不适和焦虑/抑郁维度报告有问题。中医治疗肺癌患者的健康效用得分和HRQoL信息可能对中国未来的支持性护理、经济评估和决策有用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94b3/8824292/ed81f02934a1/PPA-16-297-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94b3/8824292/02a3aef4eadf/PPA-16-297-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94b3/8824292/ed81f02934a1/PPA-16-297-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94b3/8824292/02a3aef4eadf/PPA-16-297-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94b3/8824292/ed81f02934a1/PPA-16-297-g0002.jpg

相似文献

1
Health-Related Quality of Life and Utility Scores of Lung Cancer Patients Treated with Traditional Chinese Medicine in China.中国接受中医药治疗的肺癌患者的健康相关生活质量和效用评分
Patient Prefer Adherence. 2022 Feb 4;16:297-306. doi: 10.2147/PPA.S344622. eCollection 2022.
2
Measurement of Health-Related Quality of Life Among Colorectal Cancer Patients Using the Vietnamese Value Set of the EQ-5D-5L.使用越南版EQ-5D-5L价值集对结直肠癌患者健康相关生活质量的测量
Patient Prefer Adherence. 2020 Dec 4;14:2427-2437. doi: 10.2147/PPA.S281500. eCollection 2020.
3
Measurement of Health-Related Quality of Life in Individuals With Rare Diseases in China: Nation-Wide Online Survey.中国罕见病患者健康相关生命质量的测量:全国范围在线调查。
JMIR Public Health Surveill. 2023 Oct 31;9:e50147. doi: 10.2196/50147.
4
Assessing health-related quality of life of patients with colorectal cancer using EQ-5D-5L: a cross-sectional study in Heilongjiang of China.采用 EQ-5D-5L 量表评估结直肠癌患者的健康相关生命质量:中国黑龙江的一项横断面研究。
BMJ Open. 2018 Dec 6;8(12):e022711. doi: 10.1136/bmjopen-2018-022711.
5
Health-related quality of life among cancer survivors in rural China.中国农村癌症幸存者的健康相关生活质量。
Qual Life Res. 2019 Mar;28(3):695-702. doi: 10.1007/s11136-018-2038-6. Epub 2018 Oct 29.
6
Health-related quality of life measured using the EQ-5D-5L: South Australian population norms.使用EQ-5D-5L量表测量的健康相关生活质量:南澳大利亚州人群常模。
Health Qual Life Outcomes. 2016 Sep 20;14(1):133. doi: 10.1186/s12955-016-0537-0.
7
Evaluating health-related quality of life in gastric cancer patients in Suzhou, China.评价中国苏州胃癌患者的健康相关生活质量。
Ann Palliat Med. 2021 Jul;10(7):8024-8033. doi: 10.21037/apm-21-1599.
8
Health-related quality of life among patients with knee osteoarthritis in Guangzhou, China: a multicenter cross-sectional study.中国广州膝骨关节炎患者的健康相关生活质量:一项多中心横断面研究。
Health Qual Life Outcomes. 2023 May 27;21(1):50. doi: 10.1186/s12955-023-02133-x.
9
EQ-5D-5L norms for the urban Chinese population in China.中国城市人群 EQ-5D-5L 量表中国常模。
Health Qual Life Outcomes. 2018 Nov 8;16(1):210. doi: 10.1186/s12955-018-1036-2.
10
Health-related quality of life assessed by EQ-5D-5L and its determinants among Chinese adults.采用 EQ-5D-5L 评估的中国成年人健康相关生活质量及其决定因素。
Front Public Health. 2024 Sep 11;12:1383781. doi: 10.3389/fpubh.2024.1383781. eCollection 2024.

引用本文的文献

1
Health-Related Quality of Life of Non-Small Cell Lung Cancer Patients Treated with Targeted Therapy: Based on the EQ-5D-5L Scale in Vietnam.接受靶向治疗的非小细胞肺癌患者的健康相关生活质量:基于越南的EQ-5D-5L量表
Asian Pac J Cancer Prev. 2025 Apr 1;26(4):1277-1283. doi: 10.31557/APJCP.2025.26.4.1277.
2
Who is Seeking Traditional Chinese Medicine (TCM) for Cancer? Insights from a Large Cohort in a Rehabilitation Clinic.哪些人在寻求中医治疗癌症?来自一家康复诊所的大型队列研究的见解。
Patient Prefer Adherence. 2025 Apr 2;19:883-896. doi: 10.2147/PPA.S509263. eCollection 2025.
3
The Application of Traditional Chinese Medicine-Derived Formulations in Cancer Immunotherapy: A Review.

本文引用的文献

1
Population norms for the EQ-5D-3L in China derived from the 2013 National Health Services Survey.中国 2013 年国家卫生服务调查的 EQ-5D-3L 人群正常值。
J Glob Health. 2021 Feb 11;11:08001. doi: 10.7189/jogh.11.08001.
2
Trends and risk factors of lung cancer in China.中国肺癌的趋势与风险因素。
Chin J Cancer Res. 2020 Dec 31;32(6):683-694. doi: 10.21147/j.issn.1000-9604.2020.06.02.
3
Preliminary Efficacy and Safety of Reishi & Privet Formula on Quality of Life Among Non-Small Cell Lung Cancer Patients Undergoing Chemotherapy: A Randomized Placebo-Controlled Trial.
中药衍生制剂在癌症免疫治疗中的应用:综述
Cancer Manag Res. 2025 Jan 11;17:23-34. doi: 10.2147/CMAR.S503071. eCollection 2025.
4
Chinese Medicine Enhancing Response Rates to Immunosuppressant PD-L1 Inhibitor and Improving the Quality of Life of Hepatocellular Carcinoma-Bearing Mice.中药提高免疫抑制剂PD-L1抑制剂的反应率并改善荷肝癌小鼠的生活质量。
Iran J Pharm Res. 2023 Apr 7;22(1):e134216. doi: 10.5812/ijpr-134216. eCollection 2023 Jan-Dec.
灵芝女贞复方制剂对化疗非小细胞肺癌患者生活质量的初步疗效和安全性:一项随机安慰剂对照试验。
Integr Cancer Ther. 2020 Jan-Dec;19:1534735420944491. doi: 10.1177/1534735420944491.
4
Efficacy and safety of TCM combined with chemotherapy for SCLC: a systematic review and meta-analysis.中医药联合化疗治疗小细胞肺癌的疗效和安全性:系统评价和荟萃分析。
J Cancer Res Clin Oncol. 2020 Nov;146(11):2913-2935. doi: 10.1007/s00432-020-03353-0. Epub 2020 Aug 14.
5
Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan.三种一线 EGFR 酪氨酸激酶抑制剂的比较疗效和成本效益:对中国台湾一家三级医院真实世界数据的分析。
PLoS One. 2020 Apr 8;15(4):e0231413. doi: 10.1371/journal.pone.0231413. eCollection 2020.
6
Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018.肺癌患者生活质量分析:2012 年至 2018 年间发表的 III 期临床试验的系统评价。
Lung Cancer. 2020 Jan;139:47-54. doi: 10.1016/j.lungcan.2019.10.022. Epub 2019 Oct 31.
7
Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer.表皮生长因子受体突变型晚期非小细胞肺癌中酪氨酸激酶抑制剂的真实世界健康效用评分和毒性。
Cancer Med. 2019 Dec;8(18):7542-7555. doi: 10.1002/cam4.2603. Epub 2019 Oct 24.
8
Health-related quality of life among patients with hypertension: population-based survey using EQ-5D-5L in Hong Kong SAR, China.高血压患者的健康相关生活质量:中国香港特别行政区基于人群的 EQ-5D-5L 调查。
BMJ Open. 2019 Sep 27;9(9):e032544. doi: 10.1136/bmjopen-2019-032544.
9
Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades.过去四十年来肺癌患者的发病率、治疗情况及生存率趋势。
Cancer Manag Res. 2019 Jan 21;11:943-953. doi: 10.2147/CMAR.S187317. eCollection 2019.
10
[Report of cancer epidemiology in China, 2015].《2015年中国癌症流行病学报告》
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005.